<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00982033</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00008625</org_study_id>
    <secondary_id>CTA study # CSPP100AUS13T</secondary_id>
    <secondary_id>GTS # 34136</secondary_id>
    <nct_id>NCT00982033</nct_id>
  </id_info>
  <brief_title>Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction</brief_title>
  <acronym>Aliskiren</acronym>
  <official_title>A Randomized, Blinded, Placebo-Controlled Six Month Treatment Trial of Aliskiren to Improve Exercise Tolerance in Older Patients With Heart Failure and Normal Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine whether treatment with aliskiren (300 mg)
      compared to placebo will improve treadmill exercise time in older (age ≥ 55 years) patients
      with heart failure and normal ejection fraction (HFNEF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart Failure with Normal Ejection Fraction (HFNEF) is the most common form of heart failure,
      particularly in older persons. However, the optimal therapy for this disorder has not been
      defined. The primary chronic symptom in HFNEF is exercise intolerance, manifested by
      shortness of breath and fatigue with exercise. This is the major determinant of quality of
      life, can be measured objectively and reproducibly and is modifiable.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise Treadmill Time</measure>
    <time_frame>Baseline, 24 week visit</time_frame>
    <description>Treadmill exercise time to exhaustion on the modified naughton protocol.
LS-mean is in effect, within-group means appropriately adjusted for the other effects in the model.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 % of subjects participating in this trial will be on the active medication, Aliskiren 300mg qd, the other 50% will be on placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50% of subjects will be randomized to placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aliskiren</intervention_name>
    <description>aliskiren 300mg qd versus placebo for 24 weeks.</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <other_name>Tekturna</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo qd for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥ 55 years of age

          -  Symptomatic HFNEF of at least 1 month duration.

          -  Reduced early diastolic mitral annular velocity by tissue Doppler

          -  Left ventricular ejection fraction (LVEF ≥ 0.50)

          -  Baseline exercise intolerance

          -  Patients who are able to provide written informed consent

          -  Stable medical therapy for 30 days prior to screening

        Exclusion Criteria:

          -  Seated blood pressure ≥ 160/90 mmHg at Visit 1 (screening)

          -  Clinically significant pulmonary disease

          -  Known history of documented EF &lt; 0.45 at any time

          -  Clinically unstable heart failure, medication changes for worsening heart failure
             symptoms within the past 4 weeks

          -  Severe anemia (Hgb &lt;10 mg/dL)

          -  Clinical evidence of uncontrolled hypo or hyperthyroidism

          -  Clinically significant valvular heart disease

          -  Surgical correction of valvular heart disease within the last year

          -  Known familial hypertrophic cardiomyopathy or hypertrophic obstructive cardiomyopathy

          -  Known restrictive cardiomyopathy or systemic illness known to be associated with
             infiltrative myocardial disease (e.g. amyloidosis, sarcoidosis, hemachromatosis)

          -  Pericardial restriction or hemodynamically significant pericardial effusion

          -  Cor pulmonal or other causes of right heart failure not related to LV dysfunction

          -  Extreme obesity (weight &gt; 325 pounds)

          -  Acute coronary syndrome within past 3 months

          -  Coronary artery revascularization within past 3 months

          -  Peripheral artery revascularization within past 3 months

          -  Acute cerebrovascular syndrome (stroke or TIA) within the past 3 months

          -  Uncontrolled symptomatic brady- or tachyarrhythmia

          -  Creatinine &gt; 2.5 mg/dl at screening

          -  Potassium &gt; 5.2 meq/l at screening

          -  Prior treatment with, hypersensitivity to, intolerance of or contra-indication to
             aliskiren

          -  Current treatment with antidepressant medication in the MAO(Monoamine Oxidase)
             inhibitor or SSRI(Selective serotonin reuptake inhibitors) class

          -  Current participation in another clinical trial

          -  Current treatment with both an ACE(Angiotensin-converting enzyme) inhibitor and an
             angiotensin receptor antagonist.

          -  Known significant bilateral renal artery stenosis

          -  Serious non-cardiovascular disease severely limiting life expectancy

          -  Previous major organ (e.g., lung, liver, heart, kidney) transplantation or on a
             transplant waiting list

          -  Any condition that is likely to prevent the patient from complying with the
             requirements of the study or completing the study (e.g., history of poor compliance,
             alcohol or drug dependency, psychiatric illness, no permanent home)

          -  Pregnant women, nursing women, and women of childbearing potential.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dalane W Kitzman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Scott JM, Haykowsky MJ, Eggebeen J, Morgan TM, Brubaker PH, Kitzman DW. Reliability of peak exercise testing in patients with heart failure with preserved ejection fraction. Am J Cardiol. 2012 Dec 15;110(12):1809-13. doi: 10.1016/j.amjcard.2012.08.015. Epub 2012 Sep 13.</citation>
    <PMID>22981266</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <results_first_submitted>October 31, 2016</results_first_submitted>
  <results_first_submitted_qc>January 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 22, 2017</results_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure with normal ejection fraction</keyword>
  <keyword>Elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aliskiren</title>
          <description>50 % of subjects participating in this trial will be on the active medication, Aliskiren 300mg qd, the other 50% will be on placebo.
aliskiren: aliskiren 300mg qd versus placebo for 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>50% of subjects will be randomized to placebo.
placebo: placebo qd for 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aliskiren</title>
          <description>50 % of subjects participating in this trial will be on the active medication, Aliskiren 300mg qd.
aliskiren: aliskiren 300mg qd for 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>50% of subjects participating in this trial will be randomized to placebo.
placebo: placebo qd for 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.3" spread="6.3"/>
                    <measurement group_id="B2" value="70.6" spread="7.7"/>
                    <measurement group_id="B3" value="69.9" spread="7.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Exercise Treadmill Time</title>
        <description>Treadmill exercise time to exhaustion on the modified naughton protocol.
LS-mean is in effect, within-group means appropriately adjusted for the other effects in the model.</description>
        <time_frame>Baseline, 24 week visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>50 % of subjects participating in this trial will be on the active medication, Aliskiren 300mg qd.
aliskiren: aliskiren 300mg qd for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50% of subjects participating in this trial will be randomized to placebo.
placebo: placebo qd for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Exercise Treadmill Time</title>
          <description>Treadmill exercise time to exhaustion on the modified naughton protocol.
LS-mean is in effect, within-group means appropriately adjusted for the other effects in the model.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="621" spread="120"/>
                    <measurement group_id="O2" value="580" spread="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="624" spread="151"/>
                    <measurement group_id="O2" value="579" spread="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LS Mean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="607" spread="13"/>
                    <measurement group_id="O2" value="605" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years, 2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aliskiren</title>
          <description>50 % of subjects participating in this trial will be on the active medication, Aliskiren 300mg qd.
aliskiren: aliskiren 300mg qd for 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>50% of subjects participating in this trial will be randomized to placebo.
placebo: placebo qd for 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea, CHF exacerbation</sub_title>
                <description>Hospitalized for dyspnea, CHF exacerbation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>small bowel obstruction</sub_title>
                <description>Surgery for small bowel obstruction.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>increased blood pressure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>atrial fibrillation and or palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>ear and or eye infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>viral symdrom and or possible thrush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain, colitis, and or virus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>leg, back and or joint pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>altered mental status</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>numbness in left arm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia and or upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>root canal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dalane W. Kitzman, M.D.</name_or_title>
      <organization>Wake Forest School of Medicine</organization>
      <phone>336-716-3274</phone>
      <email>dkitzman@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

